drugset / Trial / NCT07493148

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

NCT07493148

Phase 2 Recruiting 50 enrolled Ou Bai, MD/PHD
NaSingle-groupOpen-labelTreatment

Summary

Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.

Timeline

Start
2026-04-30
Primary completion
2029-12-30
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 20 mg Oral
Background Cyclophosphamide Other / unclassified 400 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Background Prednisone Other / unclassified 40 mg/m2 Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1 mg/m2 Intravenous